|
Virtual Meetings 2023
Meet The Professor: The Current and Future Management of Hodgkin and Non-Hodgkin LymphomaFor an up-to-date schedule of upcoming sessions, please click here. PARTICIPATING FACULTY
Ian W Flinn, MD, PhD Director, Lymphoma Research Program Sarah Cannon Research Institute Tennessee Oncology Nashville, Tennessee MODERATOR Neil Love, MD Research To Practice This activity is supported by an educational grant from AstraZeneca Pharmaceuticals LP. Agenda
MODULE 1: Selection and Sequencing of Therapy for Follicular Lymphoma MODULE 2: Current and Evolving Paradigm for the Care of Patients with Diffuse Large B-Cell Lymphoma MODULE 3: Current Management of Mantle Cell Lymphoma MODULE 4: Optimizing the Management of Hodgkin Lymphoma
Target Audience
CE Credit American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC) Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. FACULTY — The following faculty reported relevant financial relationships with ineligible entities: Dr Flinn — Consultancy (to Sarah Cannon Research Institute): AbbVie Inc, BeiGene Ltd, Century Therapeutics, Genentech, a member of the Roche Group, Genmab US Inc, Hutchison MediPharma, InnoCare Pharma, Kite, A Gilead Company, Myeloid Therapeutics Inc, Novartis, Secura Bio, Servier Pharmaceuticals LLC, TG Therapeutics Inc, Vincerx Pharma, Xencor; Research Grants (to Sarah Cannon Research Institute): 2seventy bio, AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Agios Pharmaceuticals Inc, ArQule Inc, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Bio-Path Holdings Inc, Bristol Myers Squibb, CALGB, Calibr, Celgene Corporation, Constellation Pharmaceuticals, CTI BioPharma Corp, Curis Inc, Epizyme Inc, Fate Therapeutics, Forma Therapeutics, Forty Seven Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, IGM Biosciences Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, InnoCare Pharma, Janssen Biotech Inc, Kite, A Gilead Company, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Marker Therapeutics Inc, Merck, MorphoSys, Myeloid Therapeutics Inc, Novartis, Nurix Therapeutics Inc, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Portola Pharmaceuticals Inc, Rhizen Pharmaceuticals AG, Roche Laboratories Inc, Seagen Inc, Step Pharma, Takeda Pharmaceuticals USA Inc, Tessa Therapeutics, TG Therapeutics Inc, Trillium Therapeutics Inc, Triphase Research and Development Corporation, Unum Therapeutics, Verastem Inc, Vincerx Pharma; Nonrelevant Financial Relationship (with Institution): City of Hope National Medical Center.SERIES MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab US Inc, Gilead Sciences Inc, Grail Inc, GSK, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc, and Zymeworks Inc. RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.Supporters This activity is supported by an educational grant from AstraZeneca Pharmaceuticals LP. |